All In Biotech

Drug Trial Radar · NCT04382651

Study of Efficacy and Safety of MAS825 in Patients With COVID-19

A Phase 2, Randomized, Placebo-controlled, Participant and Investigator Blinded, Multi-center Study to Assess Efficacy and Safety of MAS825 for the Treatment of SARS-CoV-2 Infected Patients With COVID-19 Pneumonia and Impaired Respiratory Function

Last checked: Nov 19, 2026Latest source record: Aug 10, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 140 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

140

Actual

Start

Jun 11, 2020

Primary completion

Jan 6, 2021

Study completion Apr 21, 2021

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
May 11, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical study was designed to assess the efficacy and safety of MAS825 for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infected patients with coronavirus disease 2019 (COVID-19) pneumonia and impaired respiratory function.

Conditions

  • COVID-19 Pneumonia, Impaired Respiratory Function

Interventions

  • MAS825Drug

    MAS825 liquid solution for intravenous infusion

  • PlaceboOther

    Placebo liquid solution for intravenous infusion

  • Standard of Care (SoC)Drug

    SoC included a variety of supportive therapies that ranged from the administration of supplementary oxygen to full intensive care support, alongside the use of antiviral treatment, convalescent plasma, corticosteroids, antibiotics or other agents.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. APACHE II Severity of Disease Score on Day 15 or on the Day of Discharge (Whichever is Earlier)Time frame: up to Day 15

Locations

21 sites in 1 country. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Chula Vista, California

  • Novartis Investigative Site

    Glendale, California

  • Novartis Investigative Site

    Irvine, California

  • Novartis Investigative Site

    La Mesa, California

  • Novartis Investigative Site

    Santa Monica, California

  • Novartis Investigative Site

    Torrance, California

  • Novartis Investigative Site

    Denver, Colorado

  • Novartis Investigative Site

    Washington D.C., District of Columbia

  • Novartis Investigative Site

    Idaho Falls, Idaho

  • Novartis Investigative Site

    Alexandria, Louisiana

  • Novartis Investigative Site

    Baton Rouge, Louisiana

  • Novartis Investigative Site

    Lafayette, Louisiana

  • Novartis Investigative Site

    Boston, Massachusetts

  • Novartis Investigative Site

    Boston, Massachusetts

  • Novartis Investigative Site

    Brooklyn, New York

  • Novartis Investigative Site

    Asheville, North Carolina

  • Novartis Investigative Site

    Columbus, Ohio

  • Novartis Investigative Site

    Bend, Oregon

  • Novartis Investigative Site

    Philadelphia, Pennsylvania

  • Novartis Investigative Site

    Houston, Texas

  • Novartis Investigative Site

    Mesquite, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.